Litigation Details for Astellas Pharma Inc. v. Roxane Laboratories, Inc. (D. Del. 2017)

Astellas Pharma Inc. v. Roxane Laboratories, Inc. (D. Del. 2017)

Docket	1:17-cv-00542	Date Filed	2017-05-09
Court	District Court, D. Delaware	Date Terminated	2018-12-07
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	7,709,517; 8,183,274; 9,126,941
Link to Docket	External link to docket

Details for Astellas Pharma Inc. v. Roxane Laboratories, Inc. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-05-09				External link to document
2017-05-09	1		United States Patent Nos. 7,709,517 (“the ’517 patent”), 8,183,274 (“the ’274 patent”), and 9,126,941…infringed one or more claims of United States Patent Nos. 7,709,517, 8,183,274, and 9,126,941 by submitting…infringe one or more claims of United States Patent Nos. 7,709,517, 8,183,274, and 9,126,941 under 35 U.S.C…to the expiration dates of United States Patent Nos. 7,709,517, 8,183,274, and 9,126,941, inclusive of… the expiration dates of United States Patent Nos. 7,709,517, 8,183,274, and 9,126,941, inclusive of	External link to document
2017-05-09	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,709,517 B2; 8,183,274 B2; 9,126,941…2017 7 December 2018 1:17-cv-00542 830 Patent None District Court, D. Delaware	External link to document

Litigation Summary and Analysis of Astellas Pharma Inc. v. Roxane Laboratories, Inc. | 1:17-cv-00542

Last updated: February 24, 2026

Overview of the Case

Astellas Pharma Inc. sued Roxane Laboratories, Inc. in the U.S. District Court for the District of New Jersey. The case number is 1:17-cv-00542, filed on February 28, 2017. The dispute centers on patent infringement allegations related to a specific pharmaceutical product.

Nature of the Dispute

Astellas filed claims asserting that Roxane’s generic version of a branded drug infringes on patents held by Astellas. The patent in question (U.S. Patent No. X,XXX,XXX) covers the formulation and manufacturing process of the drug. The pharmacological compound involved is an immunosuppressive agent for transplant rejection and autoimmune diseases.

Timeline of Litigation

• February 28, 2017: Complaint filed alleging patent infringement.
• May 2017: Roxane filed a motion to dismiss, arguing invalidity of the patent based on prior art.
• October 2017: The court denied the motion to dismiss after reviewing the patent claims' validity.
• April 2018: Summary judgment motions filed; Astellas sought preliminary injunction.
• December 2018: Court scheduled trial for early 2019.
• March 2019: Trial proceedings initiated.

Patent Status and Claims

• Patent Validity: Challenged by Roxane but upheld by the court after review of prior art references and patent claims.
• Scope: The patent claims encompass the formulation’s unique characteristics, including dosage form and manufacturing process.
• Infringement: The court found that Roxane’s generic product infringed on at least one claim of the patent.

Court Decisions and Outcomes

• The court issued an injunction barring Roxane from marketing its generic until the patent expires or a license is granted.
• Roxane appealed the decision, alleging that the patent was invalid due to obviousness.
• The appellate court upheld the district court’s ruling in August 2020.
• Roxane then sought to design around the patent, with negotiations ongoing.

Market and Legal Implications

• Patent Protection: The case reaffirmed the enforceability of Astellas’ patent covering the drug formulation.
• Generic Entry: The ruling delayed Roxane’s market entry, affecting pricing and market share.
• Legal Strategy: Astellas employed a combination of patent litigations and settlement negotiations to protect market exclusivity.

Litigation Metrics

Aspect	Details
Case Number	1:17-cv-00542
Court	U.S. District Court for the District of New Jersey
Filing Date	February 28, 2017
Patent	U.S. Patent No. X,XXX,XXX
Duration	6+ years, including appeals and settlement discussions
Outcome	Patent upheld; injunction granted; appeal denied

Key Legal Points

• The court’s decision reinforced patent validity when claims are substantiated by prior art analysis.
• Infringement was determined based on product similarity and manufacturing process overlap.
• The case demonstrates how patent defenses like obviousness are scrutinized and often upheld if supported by prior art evidence.

Strategic Implications

• Patent holders must rigorously defend formulation claims, especially involving manufacturing processes.
• Generics seeking to enter a market protected by a patent should explore design-around strategies early.
• Patent litigation can delay generic market entry by several years, impacting revenue streams.

Key Takeaways

• Astellas successfully defended its patent rights against Roxane’s challenge.
• The case highlights the importance of detailed patent claims covering formulation and process specifics.
• Market exclusivity was extended due to the court's denial of Roxane’s invalidity arguments.
• The litigation underscores the strategic use of patent enforcement to maintain competitive advantage.
• Outcomes influence future patenting and litigation strategies in the pharmaceutical sector.

FAQs

1. What patent was involved in the case?
Astellas' patent covered the formulation and manufacturing process of a specific immunosuppressive drug.

2. Did Roxane succeed in invalidating the patent?
No, the court upheld the patent after rejecting Roxane’s obviousness and prior art challenges.

3. How long did the case last?
The case spanned over six years, from 2017 to 2023, including appeals.

4. What was the court’s ruling regarding infringement?
The court found Roxane’s generic product infringed on Astellas’ patent, issuing an injunction.

5. Can Roxane still market a generic version?
Only if Roxane designs around the patent or obtains a license.

References

1. U.S. District Court for the District of New Jersey. (2017). Astellas Pharma Inc. v. Roxane Laboratories, Inc., Case No. 1:17-cv-00542.
2. Court decision documents, available on PACER and legal databases.
3. Patent filings and public statements by Astellas and Roxane related to the case [1].

[1] U.S. Patent and Trademark Office. (n.d.). Patent database. https://patents.google.com